Ligand Pharmaceuticals vs Protagonist Therapeutics
LGND and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGND and PTGX compare
Protagonist Therapeutics is the larger company, worth 1.5 times as much as Ligand Pharmaceuticals ($9.4B against $6.4B).
On earnings, Protagonist Therapeutics is cheaper: it trades at 141× trailing earnings, against 141× for Ligand Pharmaceuticals.
Protagonist Therapeutics grew revenue faster over the last twelve months (34.8% versus 1.0% for Ligand Pharmaceuticals).
Protagonist Therapeutics keeps more of each dollar of sales as profit, with a net margin of 29.4% compared with 20.3% at Ligand Pharmaceuticals.
Protagonist Therapeutics scores higher on the StockData Score (12 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGND | PTGX |
|---|---|---|
| Size and price | ||
| Market cap | $6.4B | $9.4B |
| Share price | $322.75 | $144.85 |
| Change, 1 year | 74.9% | 88.9% |
| Change, 5 years | 111% | 329% |
| Beta (5Y) | 1.30 | 0.77 |
| Employees | 47 | 132 |
| StockData Score | ||
| Total score | 6 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 141× | 141× (better) |
| P/S | 25.3× (better) | 33.2× |
| P/B | 6.7× (better) | 11.1× |
| EV/EBITDA | 118× (better) | 143× |
| P/FCF | 71.0× (better) | 71.8× |
| FCF yield | 1.4% (better) | 1.4% |
| Fair value | $53.94 | $36.28 |
| Margin of safety | −498% | −299% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.0% | 34.8% (better) |
| Revenue growth, 5Y average | 10.4% (better) | 10.0% |
| Net income growth (TTM) | 5.9% | 59.3% (better) |
| EPS growth (TTM) | 18.7% | 47.1% (better) |
| Profitability | ||
| Operating margin | 10.1% | 20.7% (better) |
| Net margin | 20.3% | 29.4% (better) |
| FCF margin | 35.7% | 46.3% (better) |
| Return on equity | 5.4% | 11.0% (better) |
| Return on invested capital | 2.6% | 73.3% (better) |
| Financial health | ||
| Debt / equity | 1.17 (better) | 0.00 |
| Net debt / EBITDA | 11.26 | – |
| Interest coverage | 3.1× | – |
| Current ratio | 1.22 | 21.71 (better) |
| Altman Z-score | 3.58 | 128.91 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 114% | 117% |
| Held by insiders | 2.6% | 1.7% |
| Insider net buying, 12 months | −$33.2M (better) | −$86.9M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 14.7% |
Go deeper
- LGND stock overview
- LGND income statement
- LGND valuation and score
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.